Acute hepatitis E acquired in the United States

Kwo, P.; Balan, VJ; Ha, Carpenter; Murphy, PJ; Je, Rosenblatt; Gg, Schlauder; Gj, Dawson; Mast, E. Gijs; Krawczyński, K.; King, J. E.

doi:10.1016/0270-9139(95)94454-0

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the causative agent is not identified in 20-30% cases of sporadic acute hepatitis, HEV markers have not been examined in most of them and it is therefore necessary to keep HEVinfection in mind in a case of non-A non-B non-C hepatitis. It is also reported that HEVinfection can be zoonotic; in the US and Taiwan new HEVstrains were isolated from patients with non-A non-B non-C hepatitis and phylogenetic analyses showed that these were closely related to HEV strains isolated from pigs in the same areas (18)(19)(20)(21). In the present case, the genotype of HEV, which would have been acquired in south China, was not analyzed.…”

Section: Discussionmentioning

confidence: 66%

Acute Hepatitis E with Elevated Creatine Phosphokinase

et al. 2003

View full text Add to dashboard Cite

Acute hepatitis E is caused by infection with hepatitis E virus, which is endemic in developing countries.Recently, the numberof cases with acute hepatitis E is increasing in Japan due to increased travel to the endemic areas. This paper reports a case of a Japanese manwith acute hepatitis E who had a history of traveling to south China. Serumcreatine phosphokinasewas elevated on admission without symptoms of muscle damage (isoenzyme MM100%), and normalized in parallel with resolution of hepatitis, raising the possibility of an association between elevation of creatine phosphokinase and acute hepatitis E. However, we need to investigate further the incidence of elevation of serum creatine phosphokinase in many cases with acute viral hepatitis including hepatitis A, B, and C to determine whether muscle disorder is characteristic of acute hepatitis E. (Internal Medicine 42: 899-902, 2003)

show abstract

Section: Discussionmentioning

confidence: 66%

Acute Hepatitis E with Elevated Creatine Phosphokinase

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Only one case of HEV infection has been documented to originate in the United States (8). Thus, the finding of anti-HEV in approximately one-fifth of Baltimore blood donors, IDUs, and homosexual men was unexpected.…”

Section: Discussionmentioning

confidence: 99%

“…Anti-HEV has also been found in 0.4 to 2% of blood donors in the United States and Europe (10,16). However, in developed countries HEV infection almost never occurs without antecedent international travel (3,8). Whether serologic reactivity to HEV in developed countries represents unrecognized infection or cross-reactivity with another condition is unknown but is clinically important.…”

mentioning

confidence: 99%

Seroreactivity to hepatitis E virus in areas where the disease is not endemic

Thomas¹,

Yarbough²,

Vlahov³

et al. 1997

J Clin Microbiol

209

View full text Add to dashboard Cite

If the occurrence of hepatitis E virus antibody (anti-HEV) in regions where the disease is not endemic represents infection, rates may be greater in high-risk populations and behavioral correlates may reflect recognized transmission modes. Serum samples from 300 homosexual males, 300 injection drug users (IDUs), and 300 blood donors from Baltimore, Md., were tested for anti-HEV by enzyme immunoassay. Anti-HEV was found in an unexpectedly high percentage of homosexual men (15.9%) and IDUs (23.0%). However, anti-HEV was present in a similar proportion of blood donors (21.3%) (P > 0.05), while hepatitis A, B, and C virus antibodies were more prevalent in the high-risk groups (P < 0.001). Among homosexual men, anti-HEV was not significantly correlated with a history of hepatitis, high-risk sexual practices, or sexually transmitted infections, in contrast to hepatitis A and B antibodies. Among IDUs, anti-HEV was not significantly associated with a history of hepatitis or high-risk drug-using practices, as was found with hepatitis C antibodies. In a setting without endemic hepatitis E disease, there was no evidence that anti-HEV reflected subclinical infection. Until the basis for HEV seroreactivity in such areas is elucidated, anti-HEV results should be interpreted with caution.

show abstract

“…So viet Union, Africa, and Mexico [102]. Recent ly, the first case of acute HEV infection ac quired in the United States was reported [103], The disease occurs in both epidemic and sporadic forms, is transmitted via a fecaloral route, has a similar clinical presentation to HAV infection with jaundice, anorexia, nausea, vomiting, abdominal pain, fever, and diarrhea, but has an inordinately high mortal ity rate among pregnant woman approximat ing 18-20% [104. 105].…”

Section: Hepatitis E Virusmentioning

confidence: 99%

Hepatitis Vaccines

Petruff¹,

Bedford²,

Gordon³

et al. 1997

Dig Dis

View full text Add to dashboard Cite

Viral hepatitis accounts for substantial morbidity and mortality worldwide, To date, the molecular sequences of six hepatotropic viruses have been described and designated hepatitis A, B, C, D, E, and G. Various methods have been employed to decrease the occurrence of these diseases, and advances in vaccination strategies have aided in prevention of viral hepatitis. There are currently two FDA-approved vaccines licensed for use in the United States, aimed at eradication of hepatitis A and hepatitis B viral infection. A considerable amount of research has been devoted to the development of these vaccines, and progress has been made toward the development of vaccines aimed at the other hepatotropic viruses. In this article, the development and current status of the vaccines directed against the hepatitis viruses are reviewed.

show abstract

Acute hepatitis E acquired in the United States

Cited by 5 publications

References 0 publications

Acute Hepatitis E with Elevated Creatine Phosphokinase

Acute Hepatitis E with Elevated Creatine Phosphokinase

Seroreactivity to hepatitis E virus in areas where the disease is not endemic

Hepatitis Vaccines

Contact Info

Product

Resources

About